Chronic Spontaneous Urticaria

Latest News

May 19th 2025

By Maddi Hebebrand, MC, Associate Editor

Research reveals a significant link between TNF-alpha serum levels and the severity of chronic spontaneous urticaria, suggesting new therapeutic avenues for treatment.

May 17th 2025

Dermatology Times Spot Test: May 17, 2025

By Emma Andrus, Editor

May 14th 2025

Recludix Unveils First BTK SH2 Domain Inhibitor

By Maddi Hebebrand, MC, Associate Editor

April 18th 2025

FDA Approves Dupilumab for Adolescents and Adults With H1 Antihistamine-Refractory Chronic Spontaneous Urticaria

By Emma Andrus, Editor, Maddi Hebebrand, MC, Associate Editor

April 17th 2025

Hope on the Horizon: Expert Insights into Dupilumab for CSU

By Maddi Hebebrand, MC, Associate Editor

CME Content

Video

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Joseph Gorelick, MSN, FNP-C

Video

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Brad P. Glick, DO, MPH, FAAD

Multimedia

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Hilary Baldwin; Neal Bhatia, MD

Video

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Tina Bhutani, MD

In-Person Event

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

June 17-19, 2026

Register now!

Video

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Diego Ruiz Dasilva, MD, FAAD; Brad Glick, DO, MPH. FAAD; Peter Lio, MD

Video

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Brittany Weber MD, PhD, FACC, FAHA; Lourdes M. Perez-Chada MD, MMSc

Video

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Andrew Alexis, MD, MPH; Leon Kircik, MD

Video

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Johann Gudjonsson, MD, PhD; Christopher Bunick, MD, PhD

Video

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Andrew F. Alexis, MD, MPH; Chesahna Kindred, MD, MBA, FAAD

Video

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Douglas DiRuggiero, DMSc, MHS, PA-C; Lakshi Aldredge, MSN, ANP-BC, DCNP, FAANP

Multimedia

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Jerry Bagel, MD, MS

Video

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Hadar Lev-Tov, MD; Martina Porter, MD

Q&A: Jonathan Bernstein, MD, FAAAAI, Discusses Advances in Chronic Spontaneous Urticaria Treatments and AAAAI Data

ByEmma Andrus, Editor

March 5th 2025

At AAAAI/WAO 2025, Bernstein explored new findings on rilzabrutinib and dupilumab in CSU, highlighting treatment gaps and future therapies.

Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria

ByEmma Andrus, Editor

March 3rd 2025

Phase 3 trial results presented at AAAAI/WAO 2025 highlight dupilumab's efficacy in reducing itch severity and urticaria activity in CSU patients.

The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS

ByMaddi Hebebrand, MC, Associate Editor

February 13th 2025

Hawkes discusses urticaria subtypes, treatments, and emerging therapies like dupilumab and remibrutinib.

CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment

ByMarie Bosslett, Assistant Editor

January 23rd 2025

According to a phase 3 study, the omalizumab biosimilar saw comparable results with a good safety profile.

Chronic Spontaneous Urticaria

Latest News

CME Content

Dermalorian™ Webinar: Shedding Light on Patient-Reported Outcomes to Assess Disease Severity in Patients With Atopic Dermatitis

Where Do Biologics Fit Into the Management of Moderate-to-Severe Atopic Dermatitis?

Expert Illustrations & Commentaries™: Exploring Novel Therapeutic Targets in Acne Management

Burst CME: Targeted Therapy for Optimal Psoriasis Management

Revolutionizing Atopic Dermatitis (RAD) Conference 2026

Understanding Topical Steroid Withdrawal (TSW) in Patients With Atopic Dermatitis (AD)

Clinical Consultations™: Providing Holistic Care for Complex Cases of Psoriasis with Cardiovascular Comorbidities

Navigating Safety Data with Janus Kinase (JAK) Inhibitors in Atopic Dermatitis (AD) Management

Assessing the Evidence for OX40-OX40L Axis Inhibition for the Treatment of Atopic Dermatitis

Patient, Provider, and Caregiver Connection™: Addressing Patient Challenges With Holistic Approaches to Vitiligo Management

Cases and Conversations™: Biologic Matchmaking in Psoriasis – Finding the Right Therapy for the Right Patient

Burst CME™: Optimizing Care for Patients with Psoriasis – Incorporating a Buy-and-Bill Model for Biologic Agents into Dermatological Practice

Hidradenitis Suppurativa: Diving Deeper Into Disease Pathogenesis, Severity Assessment, and Holistic Management Approaches

Q&A: Jonathan Bernstein, MD, FAAAAI, Discusses Advances in Chronic Spontaneous Urticaria Treatments and AAAAI Data

Q&A: Thomas Casale, MD, Discusses Abstract on Dupilumab and Significant Itch, Hive Reduction in Chronic Spontaneous Urticaria

The Complex World of Urticaria: Insights from Jason Hawkes, MD, MS

CT-P39 is Just as Effective as Omalizumab for Chronic Spontaneous Urticaria Treatment

Trending on Dermatology Times

Clascoterone 5% Delivers Strong Phase 3 Hair-Growth Results

Reviewing Type 2 Inflammation Through a Different Lens

Derm Dispatch: What 'Free to Be Me' Means to Tori Spelling and Stella McDermott

How Clinicians are Navigating JAK Inhibitors and Patient Expectations in Alopecia Areata

Alpha-9 Begins First-in-Human Trial of MC1R-Targeted Radiotherapeutic